Tivic Health Celebrates a Key Milestone: IRB Approval for ncVNS Study
Tivic Health® Systems, Inc. (NASDAQ: TIVC), a leader in health technology, is excited to share its recent achievement of receiving approval from The Feinstein Institutes’ Institutional Review Board. This approval is a major advancement for the company's innovative non-invasive cervical vagus nerve stimulation (ncVNS) technology. The upcoming study will focus on improving and fine-tuning treatment parameters related to ncVNS, a method that shows great potential for addressing various health issues.
Advancing ncVNS Technology Through Clinical Research
This clinical research partnership with The Feinstein Institutes aims to leverage physiological measurements that can significantly enhance device performance. The study will target stimulation parameters to refine essential specifications, including electrode positioning and the characteristics of the electrical waveform. The information gathered will help identify suitable clinical populations and guide the design for future clinical trials.
Objectives of the Optimization Study
The comprehensive optimization study will pursue two main goals:
- Optimizing Treatment Strategies: The study intends to provide crucial data that will advance personalized treatment strategies and optimize the stimulation parameters.
- Accelerating Product Development: By refining these parameters, the development of Tivic Health's products based on ncVNS technology will be expedited, improving the time to market.
The Importance of Strategic Collaborations
Tivic Health has recently formed a partnership with Fletcher Spaght, a respected healthcare growth strategy firm. This collaboration is focused on identifying unmet medical needs that could potentially be addressed using Tivic Health’s patent-pending ncVNS system. These partnerships not only expand the potential applications but also strengthen the company’s strategy regarding clinical relevance.
Insights from Leadership
Jennifer Ernst, the CEO of Tivic Health, highlighted the integrated approach the company is taking in clinical product development and market strategies. She remarked, "We are taking an integrated approach to clinical product development and go-to-market planning for our medical-grade non-invasive VNS program. We believe this approach creates the best opportunities to generate significant new revenue based on this work." This reflects the company's dedication to innovation and leadership in the market.
Focus Areas of the Research Team
The study will be managed by The Feinstein Institute of Bioelectronic Medicine, led by Dr. Theodoros Zanos, Ph.D., an Associate Professor at the institute. He will be working closely with Dr. Blake Gurfein, Tivic Health’s Chief Scientific Officer, whose expertise is invaluable for this project. Dr. Gurfein noted, "Precision optimization is an important but often overlooked step in non-invasive neurostimulation device development." This collaboration aims to progress from proof-of-concept to validation for specific diseases in anticipated clinical trials next year.
Market Overview for Vagus Nerve Stimulation
The global market for vagus nerve stimulation is projected to grow from an estimated $8.59 billion in 2021 to $21.3 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.6% during this time frame. Tivic Health is positioning itself strategically to become a market leader by providing improved, personalized, and effective treatment solutions through its non-invasive VNS technology.
Discovering Tivic Health
Tivic Health is on the cutting edge of health technology, specializing in bioelectronic medicine. The company utilizes stimulation techniques targeting the trigeminal, sympathetic, and vagus nerve structures to deliver therapeutic solutions for chronic health conditions without relying on pharmaceuticals. Their first commercial product, ClearUP, is an FDA-approved handheld device aimed at relieving sinus pressure and has won several awards. ClearUP is clinically validated and can be purchased through various online retailers and distributors.
Frequently Asked Questions
What is ncVNS?
ncVNS refers to non-invasive cervical vagus nerve stimulation, a technique designed to improve health outcomes by targeting specific nerve structures.
Who is overseeing the ncVNS optimization study?
The study is being spearheaded by Dr. Theodoros Zanos and Dr. Blake Gurfein, both of whom possess extensive experience in neurostimulation research.
Why is Tivic Health prioritizing the optimization of treatment parameters?
Optimizing treatment parameters is crucial for tailoring care paths for patients and enhancing the effectiveness of the ncVNS technology.
What market opportunities exist for Tivic Health?
The vagus nerve stimulation market is anticipated to experience significant growth, creating substantial opportunities for Tivic Health to enhance its product offerings and increase its market share.
What products does Tivic Health offer?
Tivic Health has a range of bioelectronic medicine products, with ClearUP being its flagship device aimed at treating sinus-related issues.
